Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
Status:
Completed
Trial end date:
2020-04-24
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled
Esketamine in participants with treatment-resistant depression (TRD) in the course of Major
Depressive Disorder (MDD). The study is to determine the efficacy and dose response of three
Esketamine doses, compared with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Celon Pharma SA
Collaborator:
National Center for Research and Development, Poland